Skip to main content

Multiple sclerosis: modulation of apoptosis susceptibility by glatiramer acetate

Buy Article:

The full text article is temporarily unavailable.

We apologise for the inconvenience. Please try again later.

Abstract:

Objectives– We investigated whether therapy of multiple sclerosis (MS) with glatiramer acetate (GA) involves the modulation of programmed cell death (apoptosis) in disease-relevant T-helper lymphocytes. Material and methods– Blood was drawn from 15 relapsing–remitting MS patients both before (baseline) as well as 6, 12, and 18 weeks after GA therapy and from 15 healthy controls. Detection of apoptosis was performed in response to in vitro stimulation with GA, myelin basic protein or medium alone. Results– T-helper lymphocytes from untreated MS patients displayed an overall increased apoptosis susceptibility in vitro, compared to controls. During subsequent GA therapy, apoptosis vulnerability of these T cells in MS patients significantly declined under the initial baseline before treatment, and was finally equal in treated patients and controls. GA itself had no direct apoptosis-modulatory properties in vitro. Conclusion– Our findings indicate that therapy of multiple sclerosis with glatiramer acetate presumably involves the compensation of altered apoptosis in T-helper lymphocytes.

Keywords: apoptosis; glatiramer acetate; multiple sclerosis

Document Type: Research Article

Affiliations: 1: Division of Neuroimmunology, Department of Neurology, Charité, Berlin, Germany, 2: Department of Neurology, St Josef-Hospital, Ruhr-University Bochum, Germany, 3: Department of Neurology, Kamillusklinik, Asbach, Germany

Publication date: 2001-11-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more